TCL Archive NCI Told To “Cut Out The Nonsense,” Adequately Fund Programs At Centers Required By Mandates November 5, 1976
TCL Archive Duke Halts Third Trial; Coauthor Disputes Claim That Data Validation Was Blinded October 23, 2009
TCL Archive HCFA Firm Against Reimbursement For Patients In Clinical Trials, Lasagna Committee Hears March 24, 1989
TCL Archive Von Eschenbach takes leave of absence from NCI, resigns from C-Change board. Acting FDA commissioner’s drug approval strategy rooted in unproven science. Von Eschenbach told NCI deputies he might drop in on meetings. Who’s really in charge? October 7, 2005
